Skip to content

The genetic association study on individual difference of therapeutic effects of antipsychotic medication

The genetic association study on individual difference of therapeutic effects of atypical antipsychotic medication

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RNC-09000522
Enrollment
Unknown
Registered
2009-08-18
Start date
2008-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

Sponsors

the Sixth Hospital, Peking University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: All subjects (male or female, 18-60 years old) are Chinese of Han descents and gave written informed consent for genetic study. The patients are recruited from the outpatient and inpatient departments of psychiatric hospitals. All patients fulfill the DSM-IV criteria for schizophrenia. The total scores of the PANSS are required above than 60 when the subjects are enrolled in the study.

Exclusion criteria

Exclusion criteria: The patients will be excluded when they: a) are diagnosed as the mental retardation, alcohol or drug addiction, according to the DSM-IV; b) suffer from the severe physical diseases, such as diabetes mellitus, thyroid gland disease, hypertension, other diseases as angel-closure glaucoma, epilapsy (febrile convulsion could be included); c) ever received the sustained-release antipsychotics, ECT or clozapine therapy one month ago; d) ever suffered from severe side effects related to antipsychotics, such as NMS, EPS, TD; e) with severe suicidal ideas or obvious excitation and agitation; f) with obvious abnormal index of laboratory examination; g) with poor therapeutic compliance or without custodians; h) with QTc interphase longer than 470 mses; i) female in pregnancy or lactation periods or planning to pregnancy.

Design outcomes

Primary

MeasureTime frame
Positive and negative symptom scale (PANSS);

Countries

China

Contacts

Public ContactYUE Weihua
dryue@bjmu.edu.cn+86 010 82028321

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 20, 2026